In Vitro Effects of an Olive Polyphenol–Bromelain Formulation on U87MG Glioblastoma Cells: Viability, Cell-Cycle Distribution, Cytokine Release, and Total Antioxidant Capacity
Open Access
- 20 September 2026
- Vol. 31 (18) , 3334
Abstract
Background: Glioblastoma (GBM) remains difficult to treat, and natural bioactive formulations are being explored as experimental modifiers of tumor-associated cellular processes. This study examined a fixed-ratio olive polyphenol–bromelain formulation in U87MG cells and performed targeted phenolic characterization of its olive-derived component. Methods: Seven phenolics were quantified by LC–MS/MS. U87MG cells were exposed to the formulation or a bromelain comparator. The MTT metabolic signal, DNA-content cell-cycle distribution, IL-6, IL-10, and extracellular total antioxidant capacity (TAC) were assessed. Results: The total quantified phenolics were 483.22 mg/kg, with oleocanthal, oleuropein, and 3,4-DHPEA-EDA predominating. The formulation reduced the MTT signal more than bromelain at lower and intermediate concentrations, although the response became non-monotonic at higher concentrations. Combination-treated cells showed greater G0/G1 accumulation. Culture supernatants showed lower IL-6 and higher IL-10 and TAC relative to untreated controls. Conclusions: The formulation was associated with changes in metabolic activity, cell-cycle distribution, and extracellular cytokine/redox readouts in U87MG cells. Because no polyphenol-only arm, direct cell-death assay, complete replicate-level inferential analysis, or non-tumoral comparator was available, the findings are descriptive and do not establish synergy, cytotoxicity, mechanism, tumor selectivity, or therapeutic efficacy.Keywords
Funding Information
- Istanbul Atlas University
This publication has 30 references indexed in Scilit:
- Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-toolNature Communications, 2025
- Olive Oil Polyphenols: A Promising Approach for Cancer Prevention and TherapyFood Science & Nutrition, 2025
- Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapyCytokine & Growth Factor Reviews, 2025
- Therapeutic approaches to modulate the immune microenvironment in gliomasnpj Precision Oncology, 2024
- Immunotherapy for glioblastoma: current state, challenges, and future perspectivesCellular & Molecular Immunology, 2024
- Preclinical models of glioblastoma: limitations of current models and the promise of new developmentsExpert Reviews in Molecular Medicine, 2021
- Understanding the tumor immune microenvironment (TIME) for effective therapyNature Medicine, 2018
- Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challengesSeminars in Cancer Biology, 2016
- Bromelain inhibits nuclear factor kappa‐B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G2/M arrest to apoptosisMolecular Carcinogenesis, 2011
- Bromelain Reversibly Inhibits Invasive Properties of Glioma CellsNeoplasia, 2001